Fig. 3From: Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemiaPARP inhibitor talazoparib triggered autophagy initiation in CML cells. Analysis of autophagy markers, SQSTM1 and LC3-I/II in CML P#1 (a) and P#2 (b) cells after treatment with talazoparib (20 μM) for 48 h. Densitometric values were measured by Image J software and the data was shown as mean ± SD of three dependent experiments (**P < 0.01)Back to article page